LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 15

Search options

  1. Article ; Online: Considerations For Use of Propensity Score Matching in Specific Patient Populations-Reply.

    Zarinsefat, Arya / Shui, Amy / Stock, Peter

    JAMA surgery

    2022  Volume 157, Issue 8, Page(s) 744

    MeSH term(s) Humans ; Propensity Score
    Language English
    Publishing date 2022-05-11
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2701841-6
    ISSN 2168-6262 ; 2168-6254
    ISSN (online) 2168-6262
    ISSN 2168-6254
    DOI 10.1001/jamasurg.2022.1496
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Consent to organ offers from public health service "Increased Risk" donors decreases time to transplant and waitlist mortality.

    Kelly, Yvonne M / Zarinsefat, Arya / Tavakol, Mehdi / Shui, Amy M / Huang, Chiung-Yu / Roberts, John P

    BMC medical ethics

    2022  Volume 23, Issue 1, Page(s) 20

    Abstract: Background: The Public Health Service Increased Risk designation identified organ donors at increased risk of transmitting hepatitis B, hepatitis C, and human immunodeficiency virus. Despite clear data demonstrating a low absolute risk of disease ... ...

    Abstract Background: The Public Health Service Increased Risk designation identified organ donors at increased risk of transmitting hepatitis B, hepatitis C, and human immunodeficiency virus. Despite clear data demonstrating a low absolute risk of disease transmission from these donors, patients are hesitant to consent to receiving organs from these donors. We hypothesize that patients who consent to receiving offers from these donors have decreased time to transplant and decreased waitlist mortality.
    Methods: We performed a single-center retrospective review of all-comers waitlisted for liver transplant from 2013 to 2019. The three competing risk events (transplant, death, and removal from transplant list) were analyzed. 1603 patients were included, of which 1244 (77.6%) consented to offers from increased risk donors.
    Results: Compared to those who did not consent, those who did had 2.3 times the rate of transplant (SHR 2.29, 95% CI 1.88-2.79, p < 0.0001), with a median time to transplant of 11 months versus 14 months (p < 0.0001), as well as a 44% decrease in the rate of death on the waitlist (SHR 0.56, 95% CI 0.42-0.74, p < 0.0001). All findings remained significant after controlling for the recipient age, race, gender, blood type, and MELD. Of those who did not consent, 63/359 (17.5%) received a transplant, all of which were from standard criteria donors, and of those who did consent, 615/1244 (49.4%) received a transplant, of which 183/615 (29.8%) were from increased risk donors.
    Conclusions: The findings of decreased rates of transplantation and increased risk of death on the waiting list by patients who were unwilling to accept risks of viral transmission of 1/300-1/1000 in the worst case scenarios suggests that this consent process may be harmful especially when involving "trigger" words such as HIV. The rigor of the consent process for the use of these organs was recently changed but a broader discussion about informed consent in similar situations is important.
    MeSH term(s) HIV Infections ; Humans ; Informed Consent ; Organ Transplantation ; Tissue Donors ; Tissue and Organ Procurement ; Waiting Lists
    Language English
    Publishing date 2022-03-05
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041552-7
    ISSN 1472-6939 ; 1472-6939
    ISSN (online) 1472-6939
    ISSN 1472-6939
    DOI 10.1186/s12910-022-00757-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV.

    Zarinsefat, Arya / Gulati, Arushi / Shui, Amy / Braun, Hillary / Rogers, Rodney / Hirose, Ryutaro / Ascher, Nancy / Stock, Peter

    JAMA surgery

    2022  Volume 157, Issue 3, Page(s) 240–247

    Abstract: Importance: Kidney transplant (KT) and liver transplant (LT) in HIV-positive patients have become more widely adopted. Data looking at long-term outcomes of patient and graft survival are lacking.: Objective: To compare the long-term outcomes of KT ... ...

    Abstract Importance: Kidney transplant (KT) and liver transplant (LT) in HIV-positive patients have become more widely adopted. Data looking at long-term outcomes of patient and graft survival are lacking.
    Objective: To compare the long-term outcomes of KT and LT in HIV-positive recipients with matched HIV-negative recipients.
    Design, setting, and participants: Retrospective, single-center, cohort, study using data from 2000 to 2019. Patients were observed until death, or graft failure requiring retransplant. All HIV-positive patients who underwent KT and/or LT between 2000 and 2019 were included. Propensity matching was performed to the corresponding HIV-negative cohort, which was obtained from the University of California, San Francisco's transplant recipient registry. The data were analyzed from 2020 to 2021.
    Exposures: HIV infection.
    Main outcomes and measures: Patient and graft survival for KT and patient survival for LT. Incidence of acute rejection and its association with KT graft survival.
    Results: For KT, 655 HIV-negative recipients (mean [SD] age, 52.3 [13.6] years; 450 [68.7%] were men) and 119 HIV-positive recipients (mean [SD] age, 51.7 [9.4] years; 86 [72.3%] were men) were included. Patient survival was 79.6% (95% CI, 73.6%-86.1%) and 53.6% (95% CI, 38.9%-74.0%) at 15 years posttransplant, respectively. Graft survival was 57.0% (95% CI, 47.8%-68.0%) and 75.0% (95% CI, 65.3%-86.2%) at 15 years posttransplant, respectively. Diagnosis of HIV was not associated with worse graft survival (hazard ratio, 1.09; 95% CI, 0.61-1.97; P = .77). For LT, 80 HIV-positive recipients (mean [SD] age, 52.6 [8.2] years; 53 [66.3%] were men) and 440 HIV-negative recipients (mean [SD] age, 54.6 [12.8] years; 291 [66.1%] were men) were included. Patient survival was 75.7% (95% CI, 71.8%-79.8%) for HIV-negative LT recipients and 70.0% (95% CI, 60.6%-80.8%) for HIV-positive LT recipients at 15 years posttransplant. Diagnosis of HIV was not a statistically significant predictor of patient survival (hazard ratio, 1.36; 95% CI, 0.83-2.24; P = .22). In KT, HIV-positive patients with at least 1 episode of acute rejection had a graft survival of 52.8% (95% CI, 38.4%-72.5%; P < .001) at 15 years posttransplant, compared with 91.8% in those without AR.
    Conclusions and relevance: In this single-center cohort study, KT and LT in HIV-positive patients had comparable long-term outcomes with those in matched HIV-negative patients. The high incidence of acute rejection was associated with reduced graft survival. The findings support providing transplant to HIV-positive patients, which may be an appropriate use of transplant resources and provides equitable access for HIV-positive patients.
    MeSH term(s) Cohort Studies ; Female ; Graft Rejection/epidemiology ; Graft Survival ; HIV Infections/complications ; Humans ; Kidney ; Liver Transplantation/adverse effects ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors
    Language English
    Publishing date 2022-01-05
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2701841-6
    ISSN 2168-6262 ; 2168-6254
    ISSN (online) 2168-6262
    ISSN 2168-6254
    DOI 10.1001/jamasurg.2021.6798
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Update in preoperative risk assessment in vascular surgery patients.

    Zarinsefat, Arya / Henke, Peter

    Journal of vascular surgery

    2015  Volume 62, Issue 2, Page(s) 499–509

    Abstract: Multiple clinical factors and now serum biomarkers may aid with risk stratification in vascular surgical patients. Herein, we review and update the clinical risk models, biomarker data, and currently used noninvasive cardiac stress tests. We also review ... ...

    Abstract Multiple clinical factors and now serum biomarkers may aid with risk stratification in vascular surgical patients. Herein, we review and update the clinical risk models, biomarker data, and currently used noninvasive cardiac stress tests. We also review the most recent American Heart Association guideline changes, and suggest a pathway for risk stratification.
    MeSH term(s) Biomarkers/blood ; Exercise Test ; Heart Diseases/blood ; Heart Diseases/complications ; Heart Diseases/diagnosis ; Humans ; Models, Cardiovascular ; Practice Guidelines as Topic ; Preoperative Care ; Prognosis ; Risk Assessment ; Vascular Diseases/blood ; Vascular Diseases/complications ; Vascular Diseases/diagnosis ; Vascular Diseases/surgery ; Vascular Surgical Procedures/adverse effects ; Vascular Surgical Procedures/mortality
    Chemical Substances Biomarkers
    Language English
    Publishing date 2015-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 605700-7
    ISSN 1097-6809 ; 0741-5214
    ISSN (online) 1097-6809
    ISSN 0741-5214
    DOI 10.1016/j.jvs.2015.05.031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Single-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation.

    Zarinsefat, Arya / Hartoularos, George / Chandran, Sindhu / Yee, Chun J / Vincenti, Flavio / Sarwal, Minnie M

    bioRxiv : the preprint server for biology

    2020  

    Abstract: COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL- ... ...

    Abstract COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL-6 receptor antibody that inhibits IL-6 activity, on treatment of COVID-19, with promising findings. As part of a clinical trial looking at the effects of Tocilizumab treatment on kidney transplant recipients with subclinical rejection, we performed single-cell RNA sequencing of comparing stimulated PBMCs before and after Tocilizumab treatment. We leveraged this data to create an in vitro cytokine storm model, to better understand the effects of Tocilizumab in the presence of inflammation. Tocilizumab-treated cells had reduced expression of inflammatory-mediated genes and biologic pathways, particularly amongst monocytes. These results support the hypothesis that Tocilizumab may hinder the cytokine storm of COVID-19, through a demonstration of biologic impact at the single-cell level.
    Keywords covid19
    Language English
    Publishing date 2020-10-06
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.09.11.281782
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an

    Zarinsefat, Arya / Hartoularos, George / Rychkov, Dmitry / Rashmi, Priyanka / Chandran, Sindhu / Vincenti, Flavio / Yee, Chun J / Sarwal, Minnie M

    Frontiers in genetics

    2021  Volume 11, Page(s) 610682

    Abstract: COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL- ... ...

    Abstract COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL-6 receptor antibody that inhibits IL-6 activity, on treatment of COVID-19, with promising findings. As part of a clinical trial looking at the effects of Tocilizumab treatment on kidney transplant recipients with subclinical rejection, we performed single-cell RNA sequencing of comparing stimulated PBMCs before and after Tocilizumab treatment. We leveraged this data to create an
    Language English
    Publishing date 2021-01-05
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606823-0
    ISSN 1664-8021
    ISSN 1664-8021
    DOI 10.3389/fgene.2020.610682
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation

    Arya Zarinsefat / George Hartoularos / Dmitry Rychkov / Priyanka Rashmi / Sindhu Chandran / Flavio Vincenti / Chun J. Yee / Minnie M. Sarwal

    Frontiers in Genetics, Vol

    2021  Volume 11

    Abstract: COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL- ... ...

    Abstract COVID-19 has posed a significant threat to global health. Early data has revealed that IL-6, a key regulatory cytokine, plays an important role in the cytokine storm of COVID-19. Multiple trials are therefore looking at the effects of Tocilizumab, an IL-6 receptor antibody that inhibits IL-6 activity, on treatment of COVID-19, with promising findings. As part of a clinical trial looking at the effects of Tocilizumab treatment on kidney transplant recipients with subclinical rejection, we performed single-cell RNA sequencing of comparing stimulated PBMCs before and after Tocilizumab treatment. We leveraged this data to create an in vitro cytokine storm model, to better understand the effects of Tocilizumab in the presence of inflammation. Tocilizumab-treated cells had reduced expression of inflammatory-mediated genes and biologic pathways, particularly amongst monocytes. These results support the hypothesis that Tocilizumab may hinder the cytokine storm of COVID-19, through a demonstration of biologic impact at the single-cell level.
    Keywords single cell RNA seq ; COVID-19 ; tocilizumab (IL-6 inhibitor) ; kidney transplantation ; transcriptomics ; bioinformatics and computational biology ; Genetics ; QH426-470
    Subject code 610
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Use of the Tissue Common Rejection Module Score in Kidney Transplant as an Objective Measure of Allograft Inflammation.

    Zarinsefat, Arya / Guerra, Jose M Arreola / Sigdel, Tara / Damm, Izabella / Sarwal, Reuben / Chan-On, Chitranon / Szabo, Gyula / Aguilar-Frasco, Jorge L / Ixtlapale-Carmona, Xicohtencatl / Salinas-Ramos, Carlos / Ramirez-Martinez, Leonardo / Ramirez, Claudio / Vilatoba, Mario / Morales Buenrostro, Luis E / Alberu, Josefina M / Sarwal, Minnie M

    Frontiers in immunology

    2021  Volume 11, Page(s) 614343

    Abstract: Long-term kidney transplant (KT) allograft outcomes have not improved as expected despite a better understanding of rejection and improved immunosuppression. Previous work had validated a computed rejection score, the tissue common rejection module (tCRM) ...

    Abstract Long-term kidney transplant (KT) allograft outcomes have not improved as expected despite a better understanding of rejection and improved immunosuppression. Previous work had validated a computed rejection score, the tissue common rejection module (tCRM), measured by amplification-based assessment of 11 genes from formalin-fixed paraffin-embedded (FFPE) biopsy specimens, which allows for quantitative, unbiased assessment of immune injury. We applied tCRM in a prospective trial of 124 KT recipients, and contrasted assessment by tCRM and histology reads from 2 independent pathologists on protocol and cause biopsies post-transplant. Four 10-μm shaves from FFPE biopsy specimens were used for RNA extraction and amplification by qPCR of the 11 tCRM genes, from which the tCRM score was calculated. Biopsy diagnoses of either acute rejection (AR) or borderline rejection (BL) were considered to have inflammation present, while stable biopsies had no inflammation. Of the 77 biopsies that were read by both pathologists, a total of 40 mismatches in the diagnosis were present. The median tCRM scores for AR, BL, and stable diagnoses were 4.87, 1.85, and 1.27, respectively, with an overall significant difference among all histologic groups (Kruskal-Wallis, p < 0.0001
    MeSH term(s) Allografts/immunology ; Biomarkers/metabolism ; Biopsy ; Female ; Graft Rejection/diagnosis ; Graft Rejection/genetics ; Graft Rejection/immunology ; Graft Rejection/metabolism ; Graft Survival/immunology ; Humans ; Immunosuppression/methods ; Inflammation/genetics ; Inflammation/metabolism ; Kidney Transplantation ; Logistic Models ; Male ; Middle Aged ; Prospective Studies ; Real-Time Polymerase Chain Reaction ; Transcriptome/genetics ; Transplantation, Homologous
    Chemical Substances Biomarkers
    Language English
    Publishing date 2021-02-03
    Publishing country Switzerland
    Document type Controlled Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2020.614343
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Long-term follow-up of beta cell replacement therapy in 10 HIV-infected patients with renal failure secondary to type 1 diabetes mellitus.

    Roll, Garrett R / Posselt, Andrew M / Freise, Jonathan / Baird, Julia / Syed, Shareef / Mo Kang, Sang / Hirose, Ryutaro / Szot, Gregory L / Zarinsefat, Arya / Feng, Sandy / Worner, Giulia / Sarwal, Minnie / Stock, Peter G

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

    2020  Volume 20, Issue 8, Page(s) 2091–2100

    Abstract: The approach to transplantation in human immunodeficiency virus (HIV)-positive patients has been conservative due to fear of exacerbating an immunocompromised condition. As a result, HIV-positive patients with diabetes were initially excluded from beta ... ...

    Abstract The approach to transplantation in human immunodeficiency virus (HIV)-positive patients has been conservative due to fear of exacerbating an immunocompromised condition. As a result, HIV-positive patients with diabetes were initially excluded from beta cell replacement therapy. Early reports of pancreas transplant in patients with HIV described high rates of early graft loss with limited follow-up. We report long-term follow-up of islet or pancreas transplantation in HIV-positive type 1 diabetic patients who received a kidney transplant concurrently or had previously undergone kidney transplantation. Although 4 patients developed polyoma viremia, highly active antiretroviral therapy and adequate infectious prophylaxis were successful in providing protection until CD4+ counts recovered. Coordination with HIV providers is critical to reduce the risk of rejection by minimizing drug-drug interactions. Also, protocols for prophylaxis of opportunistic infections and strategies for monitoring and treating BK viremia are important given the degree of immunosuppression required. This series demonstrates that type 1 diabetic patients with well-controlled HIV and renal failure can be appropriate candidates for beta cell replacement, with a low rate of infectious complications, early graft loss, and rejection, so excellent long-term graft survival is possible. Additionally, patients with HIV and cardiovascular contraindications can undergo islet infusion.
    MeSH term(s) Diabetes Mellitus, Type 1/complications ; Follow-Up Studies ; Graft Rejection/etiology ; Graft Survival ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Seropositivity ; Humans ; Pancreas Transplantation/adverse effects ; Renal Insufficiency
    Language English
    Publishing date 2020-02-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2060594-8
    ISSN 1600-6143 ; 1600-6135
    ISSN (online) 1600-6143
    ISSN 1600-6135
    DOI 10.1111/ajt.15796
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Cell-Free DNA and CXCL10 Derived from Bronchoalveolar Lavage Predict Lung Transplant Survival.

    Yang, Joshua Y C / Verleden, Stijn E / Zarinsefat, Arya / Vanaudenaerde, Bart M / Vos, Robin / Verleden, Geert M / Sarwal, Reuben D / Sigdel, Tara K / Liberto, Juliane M / Damm, Izabella / Watson, Drew / Sarwal, Minnie M

    Journal of clinical medicine

    2019  Volume 8, Issue 2

    Abstract: Standard methods for detecting chronic lung allograft dysfunction (CLAD) and rejection have poor sensitivity and specificity and have conventionally required bronchoscopies and biopsies. Plasma cell-free DNA (cfDNA) has been shown to be increased in ... ...

    Abstract Standard methods for detecting chronic lung allograft dysfunction (CLAD) and rejection have poor sensitivity and specificity and have conventionally required bronchoscopies and biopsies. Plasma cell-free DNA (cfDNA) has been shown to be increased in various types of allograft injury in transplant recipients and CXCL10 has been reported to be increased in the lung tissue of patients undergoing CLAD. This study used a novel cfDNA and CXCL10 assay to evaluate the noninvasive assessment of CLAD phenotype and prediction of survival from bronchoalveolar lavage (BAL) fluid. A total of 60 BAL samples (20 with bronchiolitis obliterans (BOS), 20 with restrictive allograft syndrome (RAS), and 20 with stable allografts (STA)) were collected from 60 unique lung transplant patients; cfDNA and CXCL10 were measured by the ELISA-based KIT assay. Median cfDNA was significantly higher in BOS patients (6739 genomic equivalents (GE)/mL) versus STA (2920 GE/mL) and RAS (4174 GE/mL) (
    Language English
    Publishing date 2019-02-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm8020241
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top